n,n-di-n-propyldopamine profile

N,N-di-n-propyldopamine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	3106
CHEMBL ID	15564
CHEBI ID	93446
SCHEMBL ID	467093
MeSH ID	M0075170

Synonym
66185-61-3
BRD-K82577285-001-01-7
LOPAC0_000465
lopac-d-031
NCGC00015296-01
PDSP2_000633
PDSP1_000638
dpda
n,n-dipropyldopamine
NCGC00162162-02
n,n-di-n-propyldopamine
4-(2-(dipropylamino)ethyl)-1,2-benzenediol
BPBIO1_001388
BIOMOL-NT_000072
NCGC00162162-01
NCGC00015296-04
CHEMBL15564 ,
bdbm50019396
4-(2-dipropylamino-ethyl)-benzene-1,2-diol
4-(2-dipropylamino-ethyl)-benzene-1,2-diol (n,n-dipropyldopamine)
cp598zu72p ,
unii-cp598zu72p
CCG-204557
NCGC00015296-03
NCGC00015296-02
SCHEMBL467093
DTXSID50216371
CHEBI:93446
Q27165143
SDCCGSBI-0050450.P002
NCGC00015296-06
4-[2-(dipropylamino)ethyl]-1,2-benzenediol, monohydrobromide
n-dipropyldopamine hydrobromide

Class	Description
catecholamine	4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] and derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID886; AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID886; AID893
dopamine D1 receptor	Homo sapiens (human)	Potency	0.0920	0.0052	1.3022	8.1995	AID624455
NFKB1 protein, partial	Homo sapiens (human)	Potency	7.9433	0.0282	7.0559	15.8489	AID895; AID928
GLS protein	Homo sapiens (human)	Potency	0.3548	0.3548	7.9355	39.8107	AID624146
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	12.5893	0.0013	7.7625	44.6684	AID914; AID915
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	39.8107	0.0013	18.0743	39.8107	AID926; AID938
arylsulfatase A	Homo sapiens (human)	Potency	0.1694	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	19.9526	0.0355	20.9770	89.1251	AID504332
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	31.6228	0.0020	7.5337	39.8107	AID891
D(1A) dopamine receptor	Homo sapiens (human)	Potency	1.0946	0.0224	5.9449	22.3872	AID488982; AID488983
chromobox protein homolog 1	Homo sapiens (human)	Potency	28.1838	0.0060	26.1688	89.1251	AID488953
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	39.8107	0.0316	10.2792	39.8107	AID884; AID885
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	0.5012	0.0010	6.0009	35.4813	AID943
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	0.0316	1.0000	10.4756	28.1838	AID901
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	0.7569	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
D	Rattus norvegicus (Norway rat)	EC50 (µMol)	12.5000	0.0082	0.2254	0.9500	AID63378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (91)

Assay ID	Title	Year	Journal	Article
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1131683	Induction of hyperactivity in Sprague-Dawley rat at 40 mg/kg, sc pretreated for 30 mins with 0.4 mg/kg haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131687	Induction of hyperactivity in Sprague-Dawley rat at 40 mg/kg, sc pretreated for 18 hrs with 5 mg/kg reserpine and 6 hrs with 250 mg/kg alpha-methyl-p-tyrosine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131630	Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat assessed as onset of action	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131615	Inhibition of 2 Hz electric current-induced cardioaccelerator nerve stimulation in iv dosed cat by cardiotachometer analysis	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID59799	Tested in vivo for change in heart rate(HR) in dog after intravenous dose of 3 mg/kg	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID1131686	Induction of hyperactivity in Sprague-Dawley rat at 40 mg/kg, sc pretreated for 30 mins with 5 mg/kg cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131651	Induction of stereotyped behaviour in Sprague-Dawley rat administered into nucleus accumbens	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131659	Induction of stereotyped behaviour in Sprague-Dawley rat administered into nucleus accumbens in presence of 5 mg/kg aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131685	Induction of hyperactivity in Sprague-Dawley rat at 40 mg/kg, sc pretreated for 30 mins with 5 mg/kg propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131657	Induction of stereotyped behaviour in Sprague-Dawley rat administered into caudate putamen in presence of 5 mg/kg aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131681	Induction of circling behaviour in Sprague-Dawley rat administered into nucleus accumbens in presence of cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131666	Induction of hyperactivity in Sprague-Dawley rat administered into nucleus accumbens in presence of 5 mg/kg cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131679	Induction of circling behaviour in Sprague-Dawley rat administered into nucleus accumbens in presence of aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131660	Induction of hyperactivity in Sprague-Dawley rat administered into caudate putamen in presence of 5 mg/kg propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131667	Induction of stereotyped behaviour in Sprague-Dawley rat administered into nucleus accumbens in presence of 5 mg/kg cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131644	Induction of circling behaviour in sc dosed Sprague-Dawley rat in presence of 5 mg/kg propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131684	Induction of hyperactivity in Sprague-Dawley rat at 40 mg/kg, sc pretreated for 30 mins with 5 mg/kg aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131633	Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat pretreated for 30 mins with 0.4 mg/kg haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131641	Induction of circling behaviour in sc dosed Sprague-Dawley rat assessed as duration of action	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131640	Induction of circling behaviour in sc dosed Sprague-Dawley rat assessed as onset of action	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131673	Induction of circling behaviour in Sprague-Dawley rat administered into nucleus accumbens	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131631	Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat assessed as duration of action	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131662	Induction of hyperactivity in Sprague-Dawley rat administered into nucleus accumbens in presence of 5 mg/kg propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131650	Induction of hyperactivity in Sprague-Dawley rat administered into nucleus accumbens	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131635	Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat pretreated for 30 mins with 5 mg/kg propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131675	Induction of circling behaviour in Sprague-Dawley rat administered into caudate putamen in presence of aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID59794	Tested in vivo for change in heart rate (HR) in dog after intravenous dose of 30 mg/kg	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID1131639	Induction of circling behaviour in sc dosed Sprague-Dawley rat assessed as reversal of spontaneous ipsilateral to contralateral circling response	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131655	Induction of stereotyped behaviour in Sprague-Dawley rat administered into nucleus accumbens in presence of 0.2 to 0.8 mg/kg haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID167274	Ability to relax the electrically stimulated rabbit ear artery was determined	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.
AID59805	Tested in vivo for change in maximal arterial pressure (MAP) in dog after intravenous dose of 300 mg/kg	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID1131678	Induction of circling behaviour in Sprague-Dawley rat administered into nucleus accumbens in presence of haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131665	Induction of stereotyped behaviour in Sprague-Dawley rat administered into caudate putamen in presence of 5 mg/kg cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131618	Inhibition of 2 Hz electric current-induced cardioaccelerator nerve stimulation in iv dosed cat by cardiotachometer analysis in presence of 0.2 mg/kg, iv haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131628	Effect on heart rate in iv dosed cat	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131664	Induction of hyperactivity in Sprague-Dawley rat administered into caudate putamen in presence of 5 mg/kg cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131636	Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat pretreated for 30 mins with 5 mg/kg cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131623	Induction of emesis in sc dosed dog	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131632	Induction of hyperactivity in Sprague-Dawley rat at 40 mg/kg, sc	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131621	Hypotensive activity in iv dosed cat	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131656	Induction of hyperactivity in Sprague-Dawley rat administered into caudate putamen in presence of 5 mg/kg aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131622	Hypotensive activity in iv dosed cat in presence of haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131652	Induction of hyperactivity in Sprague-Dawley rat administered into caudate putamen in presence of 0.2 to 0.8 mg/kg haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131645	Induction of circling behaviour in sc dosed Sprague-Dawley rat in presence of 5 mg/kg cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131647	Effect on motor function in Sprague-Dawley rat administered into caudate putamen	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131658	Induction of hyperactivity in Sprague-Dawley rat administered into nucleus accumbens in presence of 5 mg/kg aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID63378	Dopamine receptor D1 agonist efficacy was measured with stimulation of dopamine-sensitive rat adenylate cyclase in caudate membranes	1987	Journal of medicinal chemistry, Jul, Volume: 30, Issue:7	Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.
AID167290	Inhibition of the constrictor response to electrical stimulation in rabbit ear artery.	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Dopamine receptor agonists: 3-allyl-6-chloro-2,3,4,5-tetrahydro- 1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol and a series of related 3-benzazepines.
AID1131653	Induction of stereotyped behaviour in Sprague-Dawley rat administered into caudate putamen in presence of 0.2 to 0.8 mg/kg haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131677	Induction of circling behaviour in Sprague-Dawley rat administered into caudate putamen in presence of cyproheptadine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131637	Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat pretreated for 18 hrs with 5 mg/kg reserpine and 6 hrs with 250 mg/kg alpha-methyl-p-tyrosine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID59796	Tested in vivo for change in heart rate (HR) in dog after intravenous dose of 300 mg/kg	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID1131672	Induction of circling behaviour in Sprague-Dawley rat administered into caudate putamen	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID59803	Tested in vivo for change in maximal arterial pressure (MAP) in dog after intravenous dose of 30 mg/kg	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID1131676	Induction of circling behaviour in Sprague-Dawley rat administered into caudate putamen in presence of propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131689	Agonist activity at dopamine receptor in cat right atrium assessed as inhibition of cardiaccelerator nerve stimulation rate by cardiotachometer analysis	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131674	Induction of circling behaviour in Sprague-Dawley rat administered into caudate putamen in presence of haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131663	Induction of stereotyped behaviour in Sprague-Dawley rat administered into nucleus accumbens in presence of 5 mg/kg propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131619	Inhibition of 2 Hz electric current-induced cardioaccelerator nerve stimulation in iv dosed cat by cardiotachometer analysis in presence of 2 mg/kg, iv phentolamine	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID62579	Tested in vitro for dopamine agonist activity in rabbit ear artery after at a dose of 3 mg/kg	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID59801	Tested in vivo for change in maximal arterial pressure (MAP) in dog after intravenous dose of 3 mg/kg	1983	Journal of medicinal chemistry, Jul, Volume: 26, Issue:7	4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID1131661	Induction of stereotyped behaviour in Sprague-Dawley rat administered into caudate putamen in presence of 5 mg/kg propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131626	Induction of pecking in im dosed pigeon	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131629	Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131643	Induction of circling behaviour in sc dosed Sprague-Dawley rat in presence of 5 mg/kg aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131642	Induction of circling behaviour in sc dosed Sprague-Dawley rat in presence of 0.8 mg/kg haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131654	Induction of hyperactivity in Sprague-Dawley rat administered into nucleus accumbens in presence of 0.2 to 0.8 mg/kg haloperidol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131680	Induction of circling behaviour in Sprague-Dawley rat administered into nucleus accumbens in presence of propranolol	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131627	Antagonism of apomorphine-induced pecking in im dosed pigeon treated 15 mins prior to apomorphine challenge	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131634	Induction of stereotyped behaviour in sc dosed Sprague-Dawley rat pretreated for 30 mins with 5 mg/kg aceperone	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1131617	Inhibition of 10 Hz electric current-induced cardioaccelerator nerve stimulation in iv dosed cat by cardiotachometer analysis	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	24 (58.54)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (7.32)	29.6817
2010's	5 (12.20)	24.3611
2020's	9 (21.95)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	45 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
formamide formimidic acid : A carboximidic acid that is formic acid in which the carbonyl oxygen is replaced by an imino group.. primary carboxamide : A carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.	1.97	1	carboximidic acid; formamides; monocarboxylic acid amide; one-carbon compound	solvent
histamine [no description available]	1.96	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
dihydroxyphenylalanine Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.	1.96	1	hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative	human metabolite
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	1.96	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.37	2	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
adtn ADTN: RN given refers to parent cpd without isomeric designation; structure	2.37	2
fenoldopam Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.	2.88	4	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	1.96	1	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	1.96	1	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
deoxyepinephrine Deoxyepinephrine: Sympathomimetic, vasoconstrictor agent.	1.96	1	catecholamine
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	2.36	2	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	1.96	1	barbiturates	GABAA receptor agonist
phenoxybenzamine Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.	1.96	1	aromatic amine
piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.	2.37	2	N-arylpiperazine
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	1.96	1	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
ropinirole [no description available]	1.97	1	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.65	3	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
dextroamphetamine Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.	1.96	1	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.37	2	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
2-naphthol 2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.	2.37	2	naphthol	antinematodal drug; genotoxin; human urinary metabolite; human xenobiotic metabolite; mouse metabolite; radical scavenger
paraoxon [no description available]	2.02	1	aryl dialkyl phosphate; organophosphate insecticide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; mouse metabolite
apomorphine hydrochloride, anhydrous [no description available]	1.95	1
benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide Benzenaminium, 4,4'-(3-oxo-1,5-pentanediyl)bis(N,N-dimethyl-N-2-propenyl-), Dibromide: Proposed cholinesterase inhibitor.	2.02	1
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	1.96	1	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
5,6-dihydroxy-2-dimethylaminotetralin 5,6-dihydroxy-2-dimethylaminotetralin: RN given refers to parent cpd; structure	2.37	2	tetralins
2-amino-5,6-dihydroxytetralin 2-amino-5,6-dihydroxytetralin: RN given refers to parent cpd without isomeric designation; structure	1.96	1
pergolide Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	1.96	1	diamine; methyl sulfide; organic heterotetracyclic compound	antiparkinson drug; dopamine agonist
fenoldopam mesylate [no description available]	1.96	1	benzazepine
quinpirole Quinpirole: A dopamine D2/D3 receptor agonist.. quinpirole : A pyrazoloquinoline that is (4aR,8aR)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]quinoline substituted by a propyl group at position 5. It acts as a dopamine agonist.	2.65	3	pyrazoloquinoline	dopamine agonist
methanesulfonamide [no description available]	1.97	1
2-(n,n-dimethylamino)-6,7-dihydroxytetralin [no description available]	2.65	3
2-(n,n-dipropyl)amino-5,6-dihydroxytetralin 2-(N,N-dipropyl)amino-5,6-dihydroxytetralin: RN given refers to parent cpd without isomeric designation	2.37	2
2-(n,n-dipropyl)amino-6,7-dihydroxytetralin 2-(N,N-dipropyl)amino-6,7-dihydroxytetralin: RN given refers to parent cpd	1.96	1
sk&f 85174 SK&F 85174: dopamine receptor agonist; RN given refers to parent cpd; structure given in first source	1.96	1
sk&f 89124 SK&F 89124: structure given in first source	2.66	3
2-n,n-di-n-propylamino-4,7-dimethoxyindan 2-N,N-di-n-propylamino-4,7-dimethoxyindan: dopamine receptor agonist; structure given in first source	1.96	1
n,n-dimethyldopamine N,N-dimethyldopamine: RN given refers to parent cpd	2.36	2
n-n-propyl-n-n-butyl-beta-dopamine N-n-propyl-N-n-butyl-beta-dopamine: RN given refers to parent cpd; dopamine D2 receptor agonist	1.96	1
bradykinin [no description available]	1.96	1	oligopeptide	human blood serum metabolite; vasodilator agent
ergoline Ergolines: A series of structurally-related alkaloids that contain the ergoline backbone structure.. ergoline : An indole alkaloid whose structural skeleton is found in many naturally occurring and synthetic ergolines which are known to bind to neurotransmitter receptors, such as dopamine, noradrenaline and serotonin receptors and function as unselective agonists or antagonists at these receptors.	2.88	4	diamine; ergoline alkaloid; indole alkaloid fundamental parent; indole alkaloid; organic heterotetracyclic compound
lergotrile lergotrile: RN given refers to parent cpd(8beta)-isomer	1.96	1	organic heterotetracyclic compound; organonitrogen heterocyclic compound
deoxyguanosine [no description available]	2.6	1	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
guanine [no description available]	3.01	2	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
7-deazaguanine [no description available]	2.6	1	organic molecular entity
nucleoside q Nucleoside Q: A modified nucleoside which is present in the first position of the anticodon of tRNA-tyrosine, tRNA-histidine, tRNA-asparagine and tRNA-aspartic acid of many organisms. It is believed to play a role in the regulatory function of tRNA. Nucleoside Q can be further modified to nucleoside Q*, which has a mannose or galactose moiety linked to position 4 of its cyclopentenediol moiety.. queuosine : A nucleoside found in tRNA that has an additional cyclopentenyl ring added via an NH group to the methyl group of 7-methyl-7-deazaguanosine. The cyclopentenyl ring may carry other substituents.	2.6	1	7-deazaguanine ribonucleoside

Condition	Relationship Strength	Studies
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Contact Dermatitis [description not available]	2.21	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.63	2
Itching [description not available]	2.21	1
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	2.21	1
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	2.21	1
Congenital Zika Syndrome [description not available]	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Blood Pressure, High [description not available]	2.36	2
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.36	2
Decerebrate Posturing [description not available]	1.96	1
Intraocular Pressure The pressure of the fluids in the eye.	2.37	2
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	2.65	3
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	1.95	1

n,n-di-n-propyldopamine

Description

Cross-References

Synonyms (33)

Drug Classes (1)

Protein Targets (33)

Potency Measurements

Activation Measurements

Ceullar Components (1)

Bioassays (91)

Research

Studies (41)

Market Indicators

Research Demand Index: 10.91

Study Types

n,n-di-n-propyldopamine

Description

Cross-References

Synonyms (33)

Drug Classes (1)

Protein Targets (33)

Potency Measurements

Activation Measurements

Ceullar Components (1)

Bioassays (91)

Research

Studies (41)

Market Indicators

Research Demand Index: 10.91

Study Types

Related Drugs (45)

Related Conditions (15)